What happens when you get the joint checked?

What will the provider check?

The provider checks how your joint bends and bears weight. You'll talk about walking, lifting, and sleeping. An old X-ray won't answer everything, but it may help.

Name the daily task you miss most. Tell the provider which task has become hard. No treatment choice should come before your exam.

What may QC Kinetix offer?

After the exam, QC Kinetix may offer regenerative treatments. These office procedures start with your blood or marrow. The medical provider examines you and explains each step.

Clinics call one blood choice PRP, for platelet-rich plasma. Your blood is spun to gather platelets before plasma enters your joint. Concentrated PRP needs related drawing and spinning steps.

Joint preservation is a broad term here. Ask if it means a blood procedure, marrow care, or another choice before knee or hip surgery. The provider can't know what fits before your exam.

What questions matter before you decide?

Ask whether the offer uses blood, marrow, or donor tissue. Find out which body part supplies it. Then ask where the prepared liquid will be placed.

Get the total cost in writing. Ask about soreness and other risks afterward. You won't want surprises about driving, lifting, or follow-up care.

When shouldn't you wait for that visit?

A hot, swollen joint with fever needs urgent care. So does sudden loss of weight-bearing. Don't wait on a major new injury.

After back pain, weak or numb limbs may be urgent. Lost bladder or bowel control with back pain needs quick help. Hospital care comes before a routine joint visit.

Sources

1. A retrospective comparison of 523 bone marrow aspiration procedures against 435 open iliac crest bone graft harvests found aspiration significantly reduced complications - relevant because marrow aspiration for a joint injection is a real procedure with a real, if low, complication rate.

   Hernigou P, et al. — Morbidity of graft harvesting versus bone marrow aspiration in cell regenerative therapy. Int Orthop, 2014. DOI: 10.1007/s00264-014-2318-x.

2. A CDC public health investigation confirmed culture-positive bacterial infections in 20 patients who received umbilical cord blood-derived products marketed as stem cell treatment between August 2017 and September 2018; whole-genome sequencing matched patient isolates to the product.

   Hartnett KP, et al. — Investigation of Bacterial Infections Among Patients Treated With Umbilical Cord Blood-Derived Products Marketed as Stem Cell Therapies. JAMA Netw Open, 2021. DOI: 10.1001/jamanetworkopen.2021.28615.

3. A comprehensive review of published case reports, clinical reports and media accounts catalogued the safety incidents associated with unproven stem cell interventions and the factors driving the global growth of the 'stem cell tourism' market.

   Bauer G, et al. — Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions. Stem Cells Transl Med, 2018. DOI: 10.1002/sctm.17-0282.

4. 21 CFR 1271.10(a) sets the four criteria a human cell or tissue product must meet to be regulated SOLELY under section 361 of the Public Health Service Act: it must be minimally manipulated; intended for homologous use only, as reflected by labeling and advertising; not combined with another article beyond water, crystalloids or a preserving agent; and either have no systemic effect and not depend on the metabolic activity of living cells, or else be for autologous use, use in a close blood relative, or reproductive use.

   US Code of Federal Regulations, Title 21 — 21 CFR 1271.10 - Are my HCT/P's regulated solely under section 361 of the PHS Act. , 2004.

5. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. , 2020.

6. The OARSI non-surgical management guideline evaluated 60 interventions with GRADE methodology and built its recommendations around core treatments - structured exercise, weight management and self-management education - for every patient with knee osteoarthritis, regardless of what else is added.

   Bannuru RR, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage, 2019. DOI: 10.1016/j.joca.2019.06.011.

7. In 96 patients, concentrated bone marrow aspirate contained a mean of 26.3 million nucleated cells per mL but only about 1,422 colony-forming units of connective tissue progenitors, and the nucleated cell count had negligible predictive value for how many progenitor cells were actually present (r-squared 0.28).

   Muench LN, et al. — Nucleated Cell Count Has Negligible Predictive Value for the Number of Colony-Forming Units for Connective Tissue Progenitor Cells (Stem Cells) in Bone Marrow Aspirate Harvested From the Proximal Humerus During Arthroscopic Rotator Cuff Repair. Arthroscopy, 2021. DOI: 10.1016/j.arthro.2021.01.064.